Thera Phragma is a neuroscience biotechnology company aiming to discover and develop novel therapeutics to treat neurological disorders and neurodegenerative diseases by restoring the blood-brain barrier (BBB) integrity. The BBB is responsible for the healthy function of the central nervous system (CNS) and acts as a crucial checkpoint of essential components for maintaining homeostasis.
Dysfunction of the BBB can lead to an imbalance of essential components or an accumulation of toxic molecules resulting in the progression of the aforementioned pathologies. In the present landscape, drug discovery is focused on developing therapeutics that target specific molecular components responsible for each disease model that more often than not come across crucial obstacles including but not limited to CNS-penetration efficacy or organ specificity. In contrast, our company is committed to developing a unique and unequalled CNS-shuttling platform that will monitor movement of infiltrating damaging molecules or act to promote successful delivery of CNS-penetrant therapies via regulation of the BBB.
Our strategy is to take a broader approach in which our platform technology will promote the healthy function of the BBB and therefore address several disease areas including stroke, multiple sclerosis, Alzheimer’s disease and epilepsy amongst others as well as tackle current challenges encountered by others.
